Search results
29 paź 2021 · COVID‐19 patients with positive TST showed a significantly higher rate of mild disease than those with negative TST. TST positivity is favorably associated with the course of COVID‐19. Keywords: Mycobacterium tuberculosis, pathogenesis, prognosis, SARS‐COV‐2, tuberculin skin test.
- Clinical impact of COVID-19 on tuberculosis - PMC - National Center for ...
Disruption in healthcare and restrictions linked to COVID-19...
- Clinical impact of COVID-19 on tuberculosis - PMC - National Center for ...
13 maj 2024 · Treatment approaches for TB-COVID co-infection displayed minimal evolution since 2021. Converging findings from diverse studies underscored increased hospitalization risks, extended recovery periods, and accelerated mortality compared to single COVID-19 cases.
COVID-19 patients with positive TST showed a significantly higher rate of mild disease than those with negative TST. TST positivity is favorably associated with the course of COVID-19. Keywords: Mycobacterium tuberculosis; SARS-COV-2; pathogenesis; prognosis; tuberculin skin test.
In this paper, we examine how COVID-19 has impacted the different layers of TB care presented in the model and explore how we can leverage some of the lessons and outcomes of the COVID-19 pandemic to strengthen the global TB response.
3 mar 2021 · The univariate analysis showed a positive relationship between older age, having underlying diseases, and positive tuberculin skin test results with the outcome of COVID-19. We also found a lower frequency of BCG scar among patients with death outcomes than recovered ones.
The COVID-19 pandemic has severely disrupted tuberculosis control efforts and services, particularly in countries with a high burden of tuberculosis. 1,2 Resources dedicated to identifying and treating tuberculosis have been diverted to the COVID-19 response, with direct effects on tuberculosis programmes.
1 gru 2022 · Disruption in healthcare and restrictions linked to COVID-19 pandemic have also had a serious impact on TB treatment: the reduction in the delivery of therapies has had repercussions in particular on the forms DR-TB (drug-resistant TB) and XDR-TB (extensively drug-resistant TB) with a decrease in 19% and 37%.
